Hôpital Bichat, 46 Rue Henri Huchard, Paris 75018, France.
Expert Rev Anticancer Ther. 2009 Dec;9(12):1737-43. doi: 10.1586/era.09.150.
Gonadotrophin-releasing hormone (GnRH) receptor blockers (antagonists) are the latest addition to the hormonal therapy armamentarium for patients with prostate cancer. In contrast to the GnRH agonists, GnRH blockers have an immediate onset of action and do not cause an initial surge in testosterone levels that can lead to clinical flare in patients with advanced disease. Degarelix (Firmagon is a new GnRH blocker that has recently been approved by the EMEA and US FDA for the treatment of men with hormone-sensitive advanced prostate cancer. In this article, we briefly review the Phase III trial data for degarelix 240/80 mg (licensed dose) versus leuprolide 7.5 mg that led to these recent approvals.
促性腺激素释放激素（GnRH）受体阻滞剂（拮抗剂）是前列腺癌患者激素治疗手段的最新补充。与 GnRH 激动剂不同，GnRH 阻滞剂具有即刻起效的作用，不会引起睾酮水平的初始激增，从而导致晚期疾病患者出现临床恶化。地加瑞克（Firmagon）是一种新的 GnRH 阻滞剂，最近已获得 EMEA 和美国 FDA 的批准，用于治疗激素敏感的晚期前列腺癌男性患者。本文简要回顾了导致这些最近批准的地加瑞克 240/80mg（许可剂量）与亮丙瑞林 7.5mg 的 III 期临床试验数据。
